The company said the Virginia facility "would be AstraZeneca’s largest single manufacturing investment in the world." The proposed site was not disclosed.

Governor Glenn Youngkin announced Monday that AstraZeneca selected Virginia for a multi-billion-dollar manufacturing center

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy.

AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to go somewhere in Virginia.

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several manufacturing facilities in several states.

AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment.

That’s how long it took from the time AstraZeneca CEO Pascal Soriot greeted Virginia Governor Glenn Youngkin in his London office to announcing a $4 billion manufacturing facility in the state at a press conference in Washington yesterday.